Pharvaris

Pharvaris is a late-stage biopharmaceutical company developing oral therapies for the treatment of bradykinin-mediated angioedema, specifically hereditary angioedema (HAE). The company focuses on the discovery and clinical development of novel bradykinin B2 receptor antagonists to address unmet medical needs. Its pipeline includes investigational treatments designed to provide patients with oral alternatives to existing injectable therapies.